Experimental CAR-T therapy targets tough leukemia
Disease control
Terminated
This early-stage trial is testing a new treatment called CT0991, which uses specially engineered immune cells (CAR-T cells) to fight acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study involves 24 adults aged 18-75 and aims to check saf…
Phase: PHASE1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC